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Abstract
Autosomal dominant hyper-IgE syndrome caused by dominant-negative loss-of-function mutations in signal transducer and
activator of transcription factor 3 (STAT3) (STAT3-HIES) is a rare primary immunodeficiency with multisystem pathology. The
quality of life in patients with STAT3-HIES is determined by not only the progressive, life-limiting pulmonary
disease, but also significant skin disease including recurrent infections and abscesses requiring surgery. Our early
report indicated that hematopoietic stem cell transplantation might not be effective in patients with STAT3-HIES,
although a few subsequent reports have reported successful outcomes. We update on progress of our patient now
with over 18 years of follow-up and report on an additional seven cases, all of whom have survived despite
demonstrating significant disease-related pathology prior to transplant. We conclude that effective cure of the immunological
aspects of the disease and stabilization of even severe lung involvement may be achieved by allogeneic hematopoietic stem cell
transplantation. Recurrent skin infections and abscesses may be abolished. Donor TH17 cells may produce comparable levels of
IL17A to healthy controls. The future challenge will be to determine which patients should best be offered this treatment and at
what point in their disease history.
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Introduction
Autosomal dominant hyper-IgE syndrome is a rare primary
immunodeficiency (PID) with multisystem pathology [1],
caused by dominant-negative loss-of-function (LOF) muta-
tions in signal transducer and activator of transcription factor
3 (STAT3) [2, 3] (STAT3-HIES). STAT3 is integral to lym-
phocyte development and differentiation. STAT3-deficient
humans and mice have impaired cellular and humoral immune
responses [4, 5], explaining the diverse immunologic manifes-
tations [2–4]. In the context of infection, there is poor differ-
entiation of T lymphocytes into TH17 cells, resulting in low
IL17 and IL22 production [6], which contributes to suscepti-
bility to encapsulated organisms and fungi.
HSCT was initially reported as unsuccessful in STAT3-
HIES by our group [7]. Based on this impression, supportive
treatment has been largely adopted [1], but many patients
develop severe life-limiting pulmonary disease. However,
over the years, eight case reports of allogeneic hematopoietic
stem cell transplant (HSCT) for STAT3-HIES have been pub-
lished [7–12], three of them performed following the diagno-
sis of non-Hodgkin’s B cell lymphoma, which is a known
complication of this primary immunodeficiency [8]. In these
eight cases, five patients had received myeloablative condi-
tioning regimens, while three had reduced-intensity condition-
ing. Seven patients, including two with Hodgkin’s lymphoma,
were recently reported as alive and well 4–20 years following
report of HSCT [13], while one patient had died from the pre-
existing lymphoma post-transplant [10].
We initially reported failure of HSCT to resolve or cure the
immune defect in our first patient. However, we now ac-
knowledge that STAT3-HIES patients have experienced
sustained benefit from HSCT. At the time of our report, the
molecular cause of STAT3-HIES was unknown, and we
based our statements on failure to normalize the serum IgE
level and an apparent failure to change the immunological
defect. We have now shown that the IL17A levels of that
patient approaches normal (although not measured pre-
transplant) and memory B-lymphocytes are present. We now
report a series of eight patients successfully treated with
HSCT in the UK, including the long-term follow up of our
previously reported patient [7].
Methods
We conducted a retrospective review of medical records of
STAT3-HIES patients from two UK transplant centers for
PID. We included only patients with confirmed dominant-
negative STAT3 mutations who have undergone allogeneic
HSCT. We recorded pre-transplant co-morbidities, condition-
ing, outcome, and on-going co-morbidities in eight patients
who received nine transplants.
In selected patients for whom samples were available,
IL17A levels were measured by Luminex (Bio-Plex, Biorad,
UK) [14], 24 hours after stimulation in whole blood (96
Costar-F plates, 1:5 diluted in RPMI) of healthy controls and
patients. Stimulations were performed using PHA (Sigma-
Aldrich, 10 μg/ml) and compared with unstimulated medium
samples. Data were compared with historic controls, which
had been stimulated under identical conditions. P values were
calculated using the two-tailed Mann-Whitney test or the
Wilcoxon matched pairs test, excluding the data of P5 before
HSCT.
Parents, and, where appropriate, patients consented to the
procedure and data collection.
Results
Transplants were performed between 1996 and 2019.
Demographic data, genetic mutation, and pre-HSCT clinical
status are summarized in Table 1. All patients had dominant
loss-of-function mutations in STAT3 with a classical clinical
phenotype, and all had significant lung or skin-related com-
plications prior to HSCT.
Details of conditioning regimen, cell source, and graft-
versus-host disease (GvHD) prophylaxis are detailed in
Table 2. One patient received conventional myeloablative
conditioning, four received reduced-toxicity myeloablative
conditioning, and three received reduced intensity condition-
ing, one of whom rejected and was successfully re-
transplanted following a reduced-toxicity myeloablative regi-
men (patient six). All inoculi were matched at 10/10 HLA-
loci, apart from the first product for patient six, which was a 9/
10 match (DQ mismatch).
All patients survived and no patient experienced significant
GvHD. Seven patients had complete or high level (>90%)
donor chimerism and one had partial chimerism; however,
all had improvement in immune phenotype, with a reduction
in clinical symptoms, halting of progression of lung disease
and improvement in skin infections. Non-immune manifesta-
tions showed variable improvement, with one patient devel-
oping further fractures and two patients demonstrating wors-
ening scoliosis post-transplant. One patient has recently had
vasculopathy with an ST segment elevation myocardial in-
farction with ectatic coronary vasculature [12]. Patient clinical
status post-HSCT are summarized in Table 3.
In the one patient (patient 5) for whom pre- and post-
transplant IL17A levels were available, IL17A was higher
post-transplant. For patients 2, 3, and 4, IL17A levels were
present post-transplant, but lower than controls (Fig. 1).
Patient 1 had significant pulmonary infection (complicated
cystic bronchiectasis with Pseudomonas infection and wide-
spread Aspergillus infection leading to pulmonary hyperten-











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































bronchopleural fistula. He subsequently developed a
Staphylococcus aureus pericarditis requiring surgical drain-
age, complicated by prolonged air leak. Transplantation at
age 7 years was relatively uncomplicated. There was no viral
re-activation, progression of chest lesions, or acute graft ver-
sus host disease. Six years post-transplant, his eczema had
resolved and he was no longer getting significant respiratory
infections. Immunoglobulin support has ceased, and normal
vaccine and T-lymphocyte proliferative responses have been
demonstrated. His scoliosis, exacerbated by his two previous
left sided lobectomies, had deteriorated requiring spinal fusion
surgery. Following this, his right lower airway integrity has
been compromised, severely impairing his respiratory capac-
ity. He now is reliant on overnight CPAP and can only ambu-
late short distances.
Patient 2 experienced frequent staphylococcal skin infec-
tions and cystic bronchiectasis infected with Pseudomonas,
because of which transplantation was offered when aged 6
years. Despite 100% donor chimerism, the procedure was
initially described as unsuccessful [7] because of continued
elevated serum IgE. However, long-term follow-up confirmed
sustained clinical improvement with no further respiratory or
skin infections. Serum IgE levels diminished and remained
reduced, and immunoglobulin support is no longer required.
She developed thoracolumbar scoliosis, arterial hypertension,
and gonadal failure. With 20 years follow-up, pulmonary sta-
tus includes stable lingular bronchiectasis and non-
progressive right upper lobe pulmonary cysts.
Patient 3 experienced frequent severe bronchopneumonias
and progressive bronchiectasis despite immunoglobulin re-
placement, as well as osteopenia and lumbar vertebrae com-
pression fractures. Transplantation at 13 years was relatively
uneventful, and 13 years post-transplant, he demonstrates
100% donor chimerism with reduced serum IgE levels.
Lung function has improved to normal values. Hemoptysis
has stopped, and there is no computerized tomographic evi-
dence of pulmonary disease progression. An increase in
IL17A production after polyclonal stimulation was demon-
strated post-HSCT (Fig. 2), and TH17 cells display normal
response to IFN-γ and IL12 and normal IL12 production (data
not shown). However, at 11 years post-HSCT, he sustained an
anterior myocardial infarction, accompanied by classical clin-
ical, electrocardiographic and biochemical signs and parame-
ters. Angiography revealed proximal ectasia causing mid-
vessel occlusion of his left anterior descending coronary artery
but otherwise unobstructed coronary vessels. He was com-
menced on aspirin 75 mg for 3 months with rivaroxaban
2.5 mg BID for 3 years and clopidogrel 75 mg long term [12].
Patient 4 developed bronchiectasis, Staphylococcus aureus
liver abscess, and recurrent skin abscesses. Severe multi-
cystic and suppurative lung disease warranted left upper lo-
bectomy. Following transplantation at age 14 years, repeat



















































































































































































































































































































































































widespread decrease in the number and size of previously
reported large cysts, and there was a clinical improvement in
the eczematous skin lesions. Post-transplant IL17A produc-
tion was normal.
Patient 5 developed multiple abscesses and pneumatoceles
during infancy leading to right upper lobectomy and broncho-
pulmonary fistula at age 13 years. Pulmonary function was
impaired prior to HSCT, aged 17 years. Non-invasive pulmo-
nary Aspergillus infection persisted post-HSCT, treated with
appropriate long-term anti-fungal therapy—at 7 months post-
transplant, and Aspergillus pericarditis was diagnosed, which
resolved with dual anti-fungal therapy by 16 months post-
transplant. Thoracic computerized tomography demonstrated
a dramatic improvement in lung appearance, and the residual
right upper lobe cavity remained stable.
Patient 6 had persistent multiple skin infections with severe
eczema and lymphadenitis through childhood and a single
lung abscess. Additionally, a persistent Staphylococcus
aureus hepatic abscess required surgical drainage on four oc-
casions. Further to this, the patient required surgical excision
of Candida albicans retroperitoneal lymphadenitis and a fun-
gal liver abscess. The patient developed bowel perforation of
unknown etiology at 6 years of age, before HSCT. An
immune-mediated acute rejection of first graft was confirmed
at day 13 post-transplant, followed by an autologous recovery.
In this period, the patient experienced an enterococcal septic
arthritis, with collapse of femoral head, gastrointestinal hem-
orrhage, and further episodes of fungal lymphadenitis. A sec-
ond transplant procedure using a reduced toxicity treosulfan-
based regimen was successful. The patient has good immune
reconstitution and has ceased immunosuppression and immu-
noglobulin replacement.
Patient 7 was first referred to pediatric care at the age of 4
weeks due of eczema and skin infections, mainly on the face
and scalp, from which Staphylococcus aureus was isolated
and treated. Serum IgE levels were elevated prompting a di-
agnosis of Hyper IgE syndrome, confirmed genetically. The
patient continued to have numerous recurrent skin abscesses,
requiring drainage over 20 times per year despite antibiotic
treatment and immunoglobulin replacement. He subsequently
developed mandibular osteomyelitis. Pulmonary disease was
limited to asthma only, with no significant infection.
Transplant was uncomplicated, and at 20 months post-
HSCT, his skin is much improved with no new infections.
He has discontinued immunoglobulin and is awaiting
vaccination.
Patient 8 presented as a neonate with staphylococcal skin
infection and went on to develop recurrent skin infection,
pneumonia, and otitis media. She demonstrated elevated se-
rum IgE with poor pneumococcal antibody titers following
vaccination and almost no TH17 cells. Her pulmonary disease
progressed with findings of Aspergillus on bronchoalveolar
Table 2 Patient transplant demographics
Patient Follow-up Cell source; HLA Match Conditioning regimen GvHD prophylaxis Acute GvHD Latest donor chimerism
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lavage leading to a diagnosis of allergic bronchopulmonary
aspergillosis, treated with antifungal therapy, corticosteroids,
and anti-IgE monoclonal antibodies. She underwent HSCT
aged 6 years with an uncomplicated course. One year post-
HSCT, she reports only dry skin with no infection. Pulmonary
function is stable and she is asymptomatic from cough or
dyspnoea. Serum IgE has fallen to 392 kU/L. She remains
on immunoglobulin replacement but has normal B lympho-
cyte numbers.
Discussion
Published data on the outcome of allogeneic HSCT for
STAT3-HIES patients are limited, perhaps stemming from
our initial report indicating non-utility [7]. A recent report
by Oikonomopoulou et al. [13] summarizes the data of 7 pa-
tients transplanted between 1998 and 2018, one of which was
the patient we originally reported in 2000 [7]. For three of
these, the transplant indication was lymphoma [9, 10], and
thus, although the STAT3-HIES was reported as cured, their
transplant indication and management could be considered
separately. The first of these patients died 6 months following
transplant from interstitial pulmonary fibrosis, although with
pre-existing abnormal immune parameters, including raised
IgE, normalized post-transplant [10]. The other two patients,
with follow up of 10 and 14 years, respectively, both with
100% donor chimerism, were reported to have normalized
immunological parameters including a normalized proportion
of TH17
+ lymphocytes. Furthermore, other abnormalities as-
sociated with STAT3-HIES, including coarse facies and oste-
oporosis, were reported to have resolved, and there was no
symptomatic development of STAT3-HIES-associated vascu-
lopathy, although it is not clear if any screening was per-
formed [9]. A further patient, transplanted because of a com-
plicated infectious history, was reported after 42 months of
follow-up. The patient had full donor chimerism and remained
infection-free after discontinuing anti-microbial prophylaxis.
Vaccine antibody responses were demonstrated and IgE nor-
malized, STAT3 signaling was restored in hematopoietic-
derived cells, and the percentage of Th17+ lymphocytes and
central memory T lymphocytes to normal ranges was
established [11]. Finally, 2 patients, transplanted for recurrent
infection, were reported with 8 and 10 years of follow-up,
respectively. Immunological parameters normalized and the
infection frequency significantly diminished, but non-
immunological features of STAT3-HIES remained, including
a propensity to recurrent fractures and development of a new
pneumatocele, associated with ≤50% donor chimerism [8].
Our current report extends follow-up of the initial patient to
over 18 years and reports on a further 7 patients, one recently
published in the context of new onset vasculopathy complica-
tions [12], thus contributing the largest series to date. Perhaps
the most remarkable observation is that despite pre-transplant
severe, progressive lung disease—itself a significant risk fac-
tor for HSCT outcome—as well as other significant pre-
transplant sequelae, all patients in our series survived.
Importantly, pulmonary disease has stabilized in all and im-
proved in some, as demonstrated on clinical, functional, and
radiological parameters (Table 1; Fig. 3). No peri-transplant
pulmonary inflammatory complications were observed, un-
like the post-HSCT course seen in many PID patients.
GvHD was infrequent and insignificant. Notably, no patients
have required further lung surgery post-HSCT. Most patients
have remained on some antimicrobial prophylaxis, in view of
treating physician concerns of recurrent infections in pre-
existing bronchiectatic lungs—despite this, control of lung
disease reported by patients has stabilized or improved.
Aspergillus infection, likely from pre-existing colonization
or infection, recurred through, or after transplantation in some,
but did not cause the severe complications usually associated
with transplant-associated aspergillosis. Other significant in-
fections reduced in frequency or resolved completely,
accepting that most patients remained on antimicrobial pro-
phylaxis. Importantly, eczema improved in all patients and
skin infections were abolished post-transplant.
STAT3 plays an important part in normal endothelial cell
















































Fig. 1 IL17A levels in healthy controls and patients post-transplant.
IL17A levels were measured by Luminex (Bio-Plex, Biorad, UK) 24
hours after stimulation in whole blood (96 Costar-F plates, 1:5 diluted
in RPMI) of healthy controls (historical and contemporary) and patients
(P2—blue diamonds, P3—blue triangles, P4—blue squares, P5 (pre and
post HSCT)—blue circles). Stimulations were done using PHA (Sigma-
Aldrich, 10 μg/ml) and compared with unstimulated medium samples
(Med)
J Clin Immunol
Fig. 2 Pre- and post-transplant peripheral blood mononuclear cells demonstrate that IL17A is absent pre-transplant and present post-transplant (patient
3), with normal control and a negative control patient who has not been transplanted (p.V637M)
J Clin Immunol
contribute to initiation of transplant-related inflammatory
complications [17]. It may be that the lack of severe post-
HSCT inflammatory complications including acute graft-
versus-host disease, observed in these patients and the previ-
ously reported cases, might be due to reduced endothelial cell
upregulation, conferred by dominant negative STAT3-LOF
mutations.
Although serum IgE levels remain above the adult refer-
ence range, they are substantially lower post-HSCT compared
with pre-HSCT levels, although, in non-transplanted patients,
IgE levels may fall over time [1]. More importantly, in those
patients for whom data were available, normal TH17 function
and associated cytokine responses are demonstrated (Fig. 1),
confirming previous reports [8, 9, 11].
As expected, many extra-immune manifestations have not
resolved post-HSCT, and patients retain coarse facial features,
as well as bone-related complications, although it is notewor-
thy that only one patient has developed fractures post-trans-
plantation. No patient has developed lymphoma to date.
Critically, however, one patient (#3) recently experienced an
anterior myocardial infarction, with evidence of thrombotic
occlusion of dilated (ectatic) coronary vessels upon angiogra-
phy. We estimated this patient’s 10-year risk of developing a
heart attack or stroke, using the QRISK3 calculator, as 0.1%,
which suggests that conventional cardiovascular risk factors
were unlikely to account for the event, and disease-associated
vasculopathy is more likely to be implicated [12]. Screening
of coronary vasculature had not been performed prior to this
event, and so it is unclear whether HSCT ameliorated, accel-
erated, or had no effect on these coronary vessels. Whether
earlier HSCT will favorably alter the pre-disposition to vascu-
lar complications documented in these patients remains to be
seen. Further research is required to establish the clinical sig-
nificance of these wider complications of STAT3-HIES and
capture the long-term impact of STAT3-HIES on patients’
quality of life across the spectrum of presentations.
Contrary to our previous assertion [7], this series, along with
other published reports, further supports the notion that allogene-
ic HSCT can improve the immunological deficit, modify the
pulmonary course in these patients, and improve the skin condi-
tion. The future challenge will be to identify which patients will
benefit from early consideration of this therapy to prevent end-
organ damage, reduce hospitalization and improve quality of life,
as well as which conditioning regimen to use. The importance of
complete or high donor chimerism is not established, and further
work is required to determine optimum conditioning regimens
and minimum effective donor chimerism level. Furthermore, it
will be particularly important to determine whether HSCT can
alter the risk of developing vascular anomalies, which may be
associated with significant morbidity and mortality.
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Fig. 3 Thoracic computerized tomography images from patient 4. a
Images taken 1 year pre-transplant showing markedly abnormal lung
parenchyma with large cysts, bullae, and cystic bronchiectasis particular-
ly in the right lower lobe in association with cylindrical bronchiectasis,
bronchial wall thickening, bronchocoeles, and reduced lung attenuation.
b Images taken 1 year post-transplant showing several thin walled pul-
monary “cysts,” similar to previous pre-transplant findings and are there-
fore most likely to result from previous infection and lung destruction.
Some regions of parenchymal distortion and scarring are also similar.
There is some bronchial dilatation and distortion in regions of scarring,
but no convincing evidence of bronchiectasis
J Clin Immunol
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